The mission of Cavalon Therapeutics, Inc is to develop best in class medicines for neurodegenerative and neuropsychiatric diseases. Cavalon has established proprietary insights and drug development strategies based on an understanding of the role of plasma membrane calcium channels in CNS diseases. Our first therapeutic programs focus on breakthrough medicines for Parkinson’s disease and Opioid Use Disorder (OUD), two large markets with significant unmet needs. Cavalon was founded by an experienced team of entrepreneurs and scientists from industry and academia. The company is built around discoveries made by Dr. James Surmeier, one of the company's co-founders, and Cavalon has access to key technology and intellectual property from Northwestern University. Cavalon Therapeutics is supported by grant funding from the Michael J. Fox Foundation for Parkinson's Research.